Crossmark

Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma

Published Online: 2021-10-20

Published Print: 2022-06

Authors

Gao, Chao

Wang, Shenghao

Shao, Weiqing

Zhang, Yu

Lu, Lu

Jia, Huliang

Zhu, Kejin

Chen, Jinhong

Dong, Qiongzhu

Lu, Ming

Zhu, Wenwei

Qin, Lunxiu
License Information

Text and Data Mining valid from 2021-10-20

Version of Record valid from 2021-10-20
More Information

Article History

Received: 15 December 2020

Accepted: 28 May 2021

First Online: 20 October 2021

Document is current